細胞生存率アッセイ市場：製品タイプ（消耗品、装置）、細胞タイプ（動物細胞、ヒト細胞、微生物細胞）、用途、エンドユーザー別-2023～2030年の世界予測

細胞生存率アッセイの世界市場は、2023年に17億9,717万米ドル、CAGR 11.31%で大きく成長し、2030年には38億2,195万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の細胞生存率アッセイ市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.細胞生存率アッセイの世界市場規模および予測は？

2.予測期間中、世界の細胞生存率アッセイ市場を形成するCOVID-19の阻害要因と影響は？

3.細胞生存率アッセイの世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.細胞生存率アッセイの世界市場における競争戦略は？

5.細胞生存率アッセイの世界市場における技術動向と規制の枠組みは？

6.細胞生存率アッセイの世界市場における主要ベンダーの市場シェアは？

7.細胞生存率アッセイの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 細胞ベースの調査への投資の増加
    • 各国の臨床試験数の増加
    • 水域をスクリーニングするための細胞生存率アッセイの利用
  • 抑制要因
    • 試薬と細胞生存率アッセイのコストが高い
  • 機会
    • 高感度・高速プロトコルの開発細胞生存率アッセイ
    • 品質管理業務における細胞生存率の採用
  • 課題
    • 細胞生存率アッセイの技術的限界
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 細胞生存率アッセイ市場：製品別

• イントロダクション
• 消耗品
• 装置

第7章 細胞生存率アッセイ市場：細胞タイプ別

• イントロダクション
• 動物細胞
• ヒト細胞
• 微生物細胞

第8章 細胞生存率アッセイ市場：用途別

• イントロダクション
• 基礎研究
• 臨床および診断用途
• 創薬と開発
• 幹細胞研究

第9章 細胞生存率アッセイ市場：エンドユーザー別

• イントロダクション
• 学術研究機関
• 病院および診断研究所
• 製薬およびバイオテクノロジー企業

第10章 南北アメリカの細胞生存率アッセイ市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の細胞生存率アッセイ市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの細胞生存率アッセイ市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CELL VIABILITY ASSAYS MARKET RESEARCH PROCESS
• FIGURE 2. CELL VIABILITY ASSAYS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CELL VIABILITY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
• FIGURE 5. CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2022 VS 2030 (%)
• FIGURE 6. CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 7. CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
• FIGURE 8. CELL VIABILITY ASSAYS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. CELL VIABILITY ASSAYS MARKET DYNAMICS
• FIGURE 10. CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. CELL VIABILITY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. CELL VIABILITY ASSAYS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CELL VIABILITY ASSAYS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CELL VIABILITY ASSAYS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 5. CELL VIABILITY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CELL VIABILITY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 8. CELL VIABILITY ASSAYS MARKET SIZE, BY ANIMAL CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CELL VIABILITY ASSAYS MARKET SIZE, BY HUMAN CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CELL VIABILITY ASSAYS MARKET SIZE, BY MICROBIAL CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. CELL VIABILITY ASSAYS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CELL VIABILITY ASSAYS MARKET SIZE, BY CLINICAL & DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CELL VIABILITY ASSAYS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CELL VIABILITY ASSAYS MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. CELL VIABILITY ASSAYS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CELL VIABILITY ASSAYS MARKET SIZE, BY HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CELL VIABILITY ASSAYS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CELL VIABILITY ASSAYS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. CELL VIABILITY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 189. CELL VIABILITY ASSAYS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 190. CELL VIABILITY ASSAYS MARKET LICENSE & PRICING

The Global Cell Viability Assays Market is forecasted to grow significantly, with a projected USD 1,797.17 million in 2023 at a CAGR of 11.31% and expected to reach a staggering USD 3,821.95 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cell Viability Assays Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cell Viability Assays Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Consumables and Instruments. The Consumables is projected to witness significant market share during forecast period.

Based on Cell Type, market is studied across Animal Cells, Human Cells, and Microbial Cells. The Animal Cells is projected to witness significant market share during forecast period.

Based on Application, market is studied across Basic Research, Clinical & Diagnostic Applications, Drug Discovery & Development, and Stem Cell Research. The Drug Discovery & Development is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutes, Hospital & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies. The Pharmaceutical & Biotechnology Companies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cell Viability Assays Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cell Viability Assays Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Viability Assays Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Viability Assays Market?

4. What is the competitive strategic window for opportunities in the Global Cell Viability Assays Market?

5. What are the technology trends and regulatory frameworks in the Global Cell Viability Assays Market?

6. What is the market share of the leading vendors in the Global Cell Viability Assays Market?

7. What modes and strategic moves are considered suitable for entering the Global Cell Viability Assays Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cell Viability Assays Market, by Product, 2022 vs 2030
• 4.3. Cell Viability Assays Market, by Cell Type, 2022 vs 2030
• 4.4. Cell Viability Assays Market, by Application, 2022 vs 2030
• 4.5. Cell Viability Assays Market, by End-User, 2022 vs 2030
• 4.6. Cell Viability Assays Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing investments in cell-based research
    • 5.1.1.2. Rising number of clinical trials in economies
    • 5.1.1.3. Utilization of cell viability assays to screen water bodies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of reagents and cell viability assays
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of highly sensitive and rapid protocol cell viability assays
    • 5.1.3.2. Adoption of cell viability in quality control operations
  • 5.1.4. Challenges
    • 5.1.4.1. Technical limitations of cell viability assay
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cell Viability Assays Market, by Product

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Instruments

7. Cell Viability Assays Market, by Cell Type

• 7.1. Introduction
• 7.2. Animal Cells
• 7.3. Human Cells
• 7.4. Microbial Cells

8. Cell Viability Assays Market, by Application

• 8.1. Introduction
• 8.2. Basic Research
• 8.3. Clinical & Diagnostic Applications
• 8.4. Drug Discovery & Development
• 8.5. Stem Cell Research

9. Cell Viability Assays Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Hospital & Diagnostic Laboratories
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Cell Viability Assays Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cell Viability Assays Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cell Viability Assays Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing